BofA lowered the firm’s price target on Carlyle to $30 from $31 and keeps an Underperform rating on the shares. In its earnings preview for the alternative asset managers, the firm notes that Q3 financial results were impacted by several headwinds that include negative markets, rising defaults and restructurings, higher interest rates, offset by positives that include realizations, investing, retail flows and improving trends. Ahead of Q3 reports, the firm adjusts its estimates and reduced its price targets for “most Alts” it covers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CG:
- Wolfe Research initiates the Alternative Asset Managers at Market Overweight
- Carlyle initiated with a Peer Perform at Wolfe Research
- Acentra Health awarded $52.3M contract from U.S. VA
- Carlyle in talks to acquire two Medtronic units for over $7B, Reuters says
- The SEC’s Crackdown on Wall Street’s Use of WhatsApp Continues